BBL launched Hulio, a biosimilar version of Abbvie's blockbuster drug Humira, in the US in July
Shares of J&J, which recently spun off its consumer health unit to focus on drugs and medical devices, rose about 2% in premarket trading
Drug maker Lupin on Tuesday said its biosimilar product Rymti, indicated for the treatment of arthritis, has received approval from the Canadian health authority. The company's product is the biosimilar of reference drug Enbrel (Etanercept). The product is indicated for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis , plaque psoriasis and paediatric plaque psoriasis. "The approval for Rymti in Canada is a key milestone in our endeavours to improve access to medicines," Lupin Biotech President Cyrus Karkaria said in a statement. It underscores the scientific success of the company's biosimilar programmes and commitment to advancing healthcare through innovation, he added.
Osteoarthritis is common in older people, but it is possible for it to develop in younger people.
Drug firm Zydus Cadila said it has received final approval from the US health regulator to market Tofacitinib extended-release tablets, used to treat rheumatoid arthritis, in the American market
The tablets will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad, Zydus Cadila said.
Some common symptoms of autoimmune diseases are pain in joints, stiffness, excessive tiredness and headaches
Current smokers are also 67% more likely to develop "seropositive" rheumatoid arthritis - when patients have antibodies in their blood that help identify the disease
The study found obesity and lack of awareness as leading factors contributing to its prevalence
Vitamin D levels may have an important role in the relationship between pain and sleep